Lidocaine 1% Injectable Solution, Sufentanil — Competitive Intelligence Brief

Lidocaine 1% Injectable Solution, Sufentanil (Lidocaine 1% Injectable Solution, Sufentanil) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + opioid analgesic combination. Area: Pain Management / Anesthesia.

phase 3 Local anesthetic + opioid analgesic combination Voltage-gated sodium channels (lidocaine); mu-opioid receptor (sufentanil) Pain Management / Anesthesia Small molecule

Target snapshot

Lidocaine 1% Injectable Solution, Sufentanil (Lidocaine 1% Injectable Solution, Sufentanil) — University of Saskatchewan. This combination drug uses lidocaine as a local anesthetic to block nerve conduction and sufentanil as an opioid analgesic to provide pain relief through mu-opioid receptor activation.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lidocaine 1% Injectable Solution, Sufentanil TARGET	Lidocaine 1% Injectable Solution, Sufentanil	University of Saskatchewan	phase 3	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu-opioid receptor (sufentanil)
bucain + fentanyl	bucain + fentanyl	University of Debrecen	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
Ropivacaine + Tramadol	Ropivacaine + Tramadol	Aga Khan University	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
Bupivacaine-fentanyl emergency group	Bupivacaine-fentanyl emergency group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
L-BUPIVACAINE ; MORPHINE	L-BUPIVACAINE ; MORPHINE	Corporacion Parc Tauli	phase 3	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (L-bupivacaine); mu-opioid receptor (morphine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + opioid analgesic combination class)

1. Aga Khan University · 1 drug in this class
2. Conrad Arnfinn Bjørshol · 1 drug in this class
3. Corporacion Parc Tauli · 1 drug in this class
4. University of Debrecen · 1 drug in this class
5. University of Saskatchewan · 1 drug in this class